This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
No takes yet. Share an insight, caveat, or question.
Claudio Campa (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: